Eligibility
Homologous deletion of this gene or loss of the protein is required for enrollment in this study
What is MTAP?
Patients without brain metastases at baseline should undergo brain MRI at this frequency
What is as clinically indicated?
This is the preferred time for participants to receive BMS-986504
What is in the AM?
This vendor is the Central Lab for this study
What is Labcorp?
BMS-986504 is an MTA-cooperative inhibitor of this protein that plays an important role in cancer cell growth and survival
What is PRMT5?
An ECOG performance status of this is required to participant in this study
What is 0-1?
Beginning at Week 48, participants must undergo body imaging at this frequency
What is every 12 weeks (+/- 7 days?
What is 1L NSCLC?
This vendor is responsible for patient registration
What is EndPoint?
This is the primary endpoint for Part 1
What is OR?
Patients must have this number of measurable disease lesions at baseline, as per tumor type
What is at least one?
The Pre-screening Period starts up to this number of days from the date of results establishing MTAP status
What is three?
This is the Pan-Ras inhibitor that will be administered to participants in Part 2, Cohort 2
What is Daraxonrasib?
This vendor is responsible for BICR and the vendor who should receive images
What is Clario?
These are the overlapping potential toxicities between BMS-986504 and Daraxonrasib
What are dermatologic (rash) and gastrointestinal (nausea, vomiting, diarrhea)?
Patients must have tumors of this type to participate in this study
What is advanced an/or metastatic?
Baseline assessments for hematology, coagulation, serum chemistry, thyroid function, and urinalysis must be performed within this number of days prior to first dose
What is 14 days?
Participants in these Cohorts will receive radiotherapy
What are Part 1, Cohort E and Part 2, Cohort 4?
These vendors will perform MTAP testing
What are Foundation Medicine and Discovery Life Sciences?
If starting at the maximum dose, this is the maximum number of dose reductions permitted for BMS-986504
What is two?
For Part 1, patients must have documented progression of disease on most recent therapy except for those enrolling in this Cohort
What is Cohort E (GBM)?
The AE/SAE reporting period begins after this required activity takes place
What is after the participant signs the ICF?
These are the chemotherapeutic agents that participants in Part 2, Cohort 2C will receive
What are Gemcitabine and Nab-paclitaxel?
This is the vendor to contact for site payments
What is IQVIA?
The FPFV for this study was on this date